If there’s a phrase to describe artificial intelligence (AI) startup Vuno, it has to be “It thinks BIG”. While most startups aim to use technology to tackle one medical condition, the Korea company decided to cast its net wide by using NVIDIA GPU-powered AI products to address diagnoses of different diseases.
Vuno’s AI algorithms are designed to capitalise on the growing pools of big data associated with a vast number of conditions. Its products address bone age assessment, neurodegenerative disorders and diseases with signs visible on chest X-rays or CT scans. In the pipeline is a product for eye abnormalities.
As former machine-learning researchers at Samsung Advanced Institute of Technology, Vuno’s co-founders saw the combination of exponential growth in high-quality medical data and a global shortage of doctors as an opportunity to build AI solutions that capitalise on both trends.
Using data provided by partner hospitals, the deep learning-based algorithms behind VUNO’s AI products are trained on dedicated GPU servers running on a mix of NVIDIA V100, P100, TITAN V and RTX GPUs.
“Speed is one of the most important factors in any medical imaging tool, yet we cannot afford to compromise accuracy. Our solutions are designed to enhance not just reading time but the accuracy of medical diagnoses, ultimately freeing up doctors to focus on provviding quality patient care,” said Kyu Hwan Jung, Chief Technology Officer of Vuno.
This week, Vuno released two free web-based services — VUNO Med-Chest X-ray COVID-19 version and VUNO Med-LungQuant COVID-19 version — that demonstrate the analysis of imaging tests of patients with lung disease suspected to be caused by COVID-19.
The systems can provide a result within five seconds from a chest X-ray and one minute from a chest CT scan.